Skip to main content
Clinical Trials/NCT03354013
NCT03354013CompletedNot Applicable

Genetic Screening and Investigating the Effect of Assisted Oocyte Activation in Couples with Diminished/aberrant Embryonic Development.

University Hospital, Ghent1 site in 1 country42 target enrollmentStarted: January 15, 2018Last updated:
Conditions
Interventions

Trial Snapshot

Phase
Not Applicable
Status
Completed
Enrollment
42
Locations
1
Primary Endpoint
Blastocyst rate

Study Overview

Brief Summary

This is an interventional comparative study at the Department of Reproductive Medicine at Ghent University Hospital. Patients with previous embryo developmental problems are eligible for the study. Patients will undergo an ICSI-AOA treatment and will also be screened for genes important in the oocyte activation and embryonic development process. Also, the calcium releasing pattern of the patients' spermatozoa will be investigated.

Detailed Description

Assisted Oocyte Activation (ICSI-AOA) will be the treatment for these patients to overcome their previous embryo developmental problems. This protocol artificially induces calcium rises in the oocyte, which mimics the natural oocyte activation process induced by the sperm factor PLCzeta. If 6 or more mature oocytes are collected at oocyte retrieval, 50%ICSI and 50% ICSI-AOA will be applied to all oocytes. The best embryo(s) will be transferred back. Rest embryo(s) will be vitrified for future cycles. Patients will be followed up.

Furthermore, an additional sperm sample will be produced to investigate the calcium inducing pattern of the patients' spermatozoa. Thereby, mouse and/or human (research-donated control oocytes) will be pre-incubated with a Ca2+ sensitive dye. Next, human spermatozoa will be injected into these mouse/human oocytes and the calcium pattern will be recorded under an inverted epifluorescence microscope.

Both partners will give a saliva sample to screen for mutations possible genes involved in oocyte activation and embryo development.

Study Design

Study Type
Interventional
Allocation
Na
Intervention Model
Single Group
Primary Purpose
Treatment
Masking
None

Eligibility Criteria

Ages
18 Years to — (Adult, Older Adult)
Sex
All
Accepts Healthy Volunteers
No

Inclusion Criteria

  • •patients with one or more previous ICSI cycles (UZ Gent) AND
  • •patients with:
  • •complete developmental arrest (no transfer), or
  • •complete developmental delay (no morula/blastocyst on Day 5), or
  • •significantly reduced blastocyst formation (≤15%)
  • •willing and able to give informed consent

Exclusion Criteria

  • •patients which went for oocyte or sperm donation
  • •patients with severe male infertility or low fertilization (<33%) after ICSI
  • •cycles requiring surgical sperm recovery procedures

Arms & Interventions

AOA, genetic screening, calcium pattern

Experimental

Clinical setting: Patients will undergo ICSI-AOA. Furthermore, patients will give a saliva sample to do genetic screening. Genes important during oocyte activation and embryo development will be investigated.

Also, calcium pattern analysis of the patients' spermatozoa will be executed.

Intervention: AOA (Procedure)

AOA, genetic screening, calcium pattern

Experimental

Clinical setting: Patients will undergo ICSI-AOA. Furthermore, patients will give a saliva sample to do genetic screening. Genes important during oocyte activation and embryo development will be investigated.

Also, calcium pattern analysis of the patients' spermatozoa will be executed.

Intervention: Genetic screening (Diagnostic Test)

AOA, genetic screening, calcium pattern

Experimental

Clinical setting: Patients will undergo ICSI-AOA. Furthermore, patients will give a saliva sample to do genetic screening. Genes important during oocyte activation and embryo development will be investigated.

Also, calcium pattern analysis of the patients' spermatozoa will be executed.

Intervention: Calcium pattern analysis (Diagnostic Test)

Outcomes

Primary Outcomes

Blastocyst rate

Time Frame: 5 days after oocyte retrieval

Blastocyst rate will be calculated and blastocyst will be scored. The best quality embryos will be transferred and/or frozen.

Secondary Outcomes

  • Live birth rate(37 - 42 weeks after last menstruation)
  • Pregnancy rate(Positive hCG 16 days after oocyte retrieval)

Investigators

Sponsor Class
Other
Responsible Party
Sponsor

Study Sites (1)

Loading locations...

Similar Trials

Genetic Screening and Assisted Oocyte... | Clinical Trial